Research finds new therapy options for children with severe juvenile idiopathic arthritis

December 21, 2012

Systemic juvenile idiopathic arthritis (SJIA) has long been considered a therapeutic orphan. Until now, the principal effective treatment has been high-dose steroids (prednisone) which are accompanied by several serious side effects. Newer treatments for other forms of JIA have not been as successful for the systemic subtype.

SJIA, an inflammatory disease, accounts for approximately 15 per cent of all children with there are currently approximately 60 children followed with SJIA at SickKids. , skin rashes, and swelling of the joints and inflammation of such as heart, liver, spleen and lymph nodes are some of the symptoms that children with SJIA face daily.

Two recent studies in the have assessed other treatment options for these patients and found two biologic drugs to be safe and effective therapies for children with SJIA. In both studies, many children who were treated with these drugs not only achieved a status of inactive disease (no fever, no ) but also showed a reduction or discontinuation steroid use.

Both international studies were conducted by the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG), which the Rheumatology Faculty at The Hospital for Sick Children (SickKids) and University of Toronto are members of. Dr. Rayfel Schneider was one of the co-investigators of both of these studies and the lead SickKids investigator.

"This group of patients is typically very challenging to treat. This research is a major step towards improved therapy options that are safe and effective." says Dr. Rayfel Schneider, Staff Physician and Project Investigator in the Department of Rheumatology at SickKids. "No unanticipated side effects were observed and those that did occur are also seen with other medications in this class."

Each therapy works by blocking specific molecules that are involved in the development and persistence of inflammation. The molecules called Interleukin-6 and Interleukin-1 have been found to be central to the pathogenesis of SJIA.

In one of the randomized controlled trials, a biologic called tocilizumab was administered to target the Interleukin-6 receptor. This study provides the first evidence in a controlled setting involving a large number of patients from around the world that blocking the action of Interleukin-6 with tocilizumab is highly effective, and safe, in patients with severe and persistent SJIA. After one year of treatment, one third of the patients reached clinically inactive disease and approximately half had stopped taking oral corticosteroids. This study was conducted at 43 centres worldwide.

In the other study the efficacy and safety of a biologic called canakinumab was assessed. Canakinumab selectively binds to Interleukin-1 beta and inactivates the signaling that leads to inflammation. The study was divided into two clinical trials; the first to provide evidence that the drug is effective in controlling fever and arthritis, and the second to further investigate the efficacy and safety of canakinumab in SJIA with active systemic features and the ability to reduce the dose of prednisone. The study demonstrated that even a single injection of the drug can result in inactive disease in as few as 15 days among 32 per cent of the treated patients. And after just seven months of treatment the drug allowed for discontinuation of steroid treatment for 45 per cent of the patients.

Overall, both therapeutic approaches proved to be safe and effective. "This appears to be a major step forward in the treatment of with SJIA and may lead to a change in the outcome of a difficult-to-manage, and potentially fatal disease," says Dr. Schneider.

Explore further: Not all juvenile arthritis is the same

Related Stories

Not all juvenile arthritis is the same

October 22, 2012
Systemic juvenile idiopathic arthritis (SJIA) is currently classified as a subtype of juvenile idiopathic arthritis but with the addition of systemic inflammation often resulting in fever, rash and serositis. New research ...

Pulmonary complications often fatal in systemic JIA

November 19, 2012
(HealthDay)—Pulmonary complications are under-recognized in systemic juvenile idiopathic arthritis (sJIA), and are often fatal, according to a study published online Nov. 8 in Arthritis Care & Research.

Injection of methotrexate not superior to oral therapy in juvenile arthritis treatment

May 30, 2012
A retrospective analysis of methotrexate (MTX) safety data found that injection of this disease-modifying anti-rheumatic drug (DMARD) was not superior to oral therapy in long-term treatment of patients with juvenile idiopathic ...

Children with juvenile arthritis have higher rates of bacterial infection

May 1, 2012
Children with juvenile idiopathic arthritis (JIA) have higher rates of hospitalized bacterial infection than children without JIA according to an observational study appearing in Arthritis & Rheumatism, a journal published ...

Recommended for you

Fluid in the knee holds clues for why osteoarthritis is more common in females

June 26, 2017
Researchers have more evidence that males and females are different, this time in the fluid that helps protect the cartilage in their knee joints.

Biologics before triple therapy not cost effective for rheumatoid arthritis

May 29, 2017
Stepping up to biologic therapy when methotrexate monotherapy fails offers minimal incremental benefit over using a combination of drugs known as triple therapy, yet incurs large costs for treating rheumatoid arthritis (RA). ...

Drug for refractory psoriatic arthritis shows promise in clinical trial

May 24, 2017
In a pivotal phase-3 clinical trial led by a Stanford University School of Medicine investigator, patients with psoriatic arthritis for whom standard-of-care pharmaceutical treatments have provided no lasting relief experienced ...

Cross-species links identified for osteoarthritis

May 17, 2017
New research from the University of Liverpool, published today in the journal npj Systems Biology and Applications, has identified 'cell messages' that could help identify the early stages of osteoarthritis (OA).

Osteoarthritis could be prevented with good diet and exercise

May 12, 2017
Osteoarthritis can potentially be prevented with a good diet and regular exercise, a new expert review published in the Nature Reviews Rheumatology reports.

Rodents with trouble walking reveal potential treatment approach for most common joint disease

May 11, 2017
Maintaining the supply of a molecule that helps to nourish cartilage prevented osteoarthritis in animal models of the disease, according to a report published in Nature Communications online May 11.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.